Ustekinumab – July 2026

  • Brand names:
    • Steqeyma®
  • Pharmaceutical Company:
    • CELLTRION HEALTHCARE AUSTRALIA PTY LTD
  • Condition/Indication: Severe chronic plaque psoriasis; Severe psoriatic arthritis; Severe Crohn disease; Complex refractory fistulising Crohn disease; Moderate to severe ulcerative colitis
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026